AIMD Expanded Global Availability of A-LRYNGO Device

The AI-guided laryngoscope reached new international markets to assist with endotracheal intubation procedures.

Updated on Sept. 22, 2026 in Artificial Intelligence

Isometric editorial illustration of a surgical laryngoscope blade, representing AI-assisted medical technology used in clinical airway management.
AIMD Inc. has expanded the global distribution of its A-LRYNGO device, an AI-powered laryngoscope designed to improve success rates in emergency intubation procedures. AI Illustration. Upload story photo >

Live Poll

Do you support the integration of AI-guided tools into standard local emergency medical procedures?

AIMD Inc. has expanded the global distribution of its A-LRYNGO device, an AI-powered laryngoscope designed to improve intubation success rates. The platform provides real-time glottis recognition to assist clinicians during high-stakes respiratory procedures.

Why it matters

Endotracheal intubation success is highly dependent on operator experience, and failures or delays can lead to cardiac arrest or death. By providing visual guidance, the device aims to reduce these complications in emergency and clinical settings.

The A-LRYNGO platform features a five-second startup time and utilizes on-device AI to eliminate the need for external servers or recurring license fees. It also supports wireless screen sharing, video recording, and image capture for clinical documentation.

The players

AIMD Inc.

This South Korea-based technology company specializes in the development of AI-driven medical diagnostic and guidance devices.

Mayo Clinic

This non-profit American academic medical center is currently conducting an evaluation of the A-LRYNGO device.

Quang Tri Department of Health

This Vietnamese regional health authority is responsible for the oversight and implementation of medical technology in its provincial hospitals.

The details

The device uses on-device artificial intelligence to perform real-time automatic glottis recognition, which aids medical professionals during critical airway management. It has been adopted by health departments in Vietnam, deployed across provincial hospitals in Laos, and is currently undergoing evaluation at the Mayo Clinic.

Timeline

  1. September 18, 2026: AIMD showcased the device at the KOICA AI Partners' Fair.

  2. September 22, 2026: AIMD announced the global expansion of the A-LRYNGO platform.

  3. November 2026: The company will showcase the device at MEDICA 2026 in Düsseldorf.

The Tech Race

The transition toward on-device artificial intelligence in medicine aims to replace server-dependent systems that require recurring licensing fees. This move positions AIMD to capture market share in regions where stable high-speed connectivity or IT infrastructure remains a barrier to adoption.

For clinicians and hospital administrators, this technology offers a simplified workflow that eliminates recurring software fees and reduces setup time to five seconds. The system enables staff to record and share medical imagery wirelessly, potentially streamlining training and improving patient outcomes.

The takeaway

Advancements in on-device AI are increasingly removing traditional infrastructure hurdles that previously limited the reach of medical technology in resource-constrained areas. Medical facilities can now leverage automated diagnostic tools without the ongoing financial burden of server-based licenses.

What happens next

AIMD Inc. will showcase the A-LRYNGO device at the MEDICA 2026 trade fair in Düsseldorf, Germany, in November 2026.

Further reading

Learn more about the latest innovations in Artificial Intelligence.

Live Poll

Do you support the integration of AI-guided tools into standard local emergency medical procedures?